Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VP01

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: C21

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 25, 2020


            Fresh human IPF lung tissue harvested from a patient during lung transplantation showed stable expression of the VP01 target, AT2R, and treatment with clinically relevant concentrations of VP01 caused a dose-dependent decrease of TGFb1.